Surveillance over cytomegalovirus (CMV) reactivation following hematopoietic stem cell transplantation: a single-center experience

Figures & data

Table 1. Characteristics of 86 patients undergoing HSCT.

Total number of patients	86
Gender (Male/Female)	46/40
Median age (range) years	42.9 (5-67)
Age of the recipient (years)	Number
<18	5
19-30	12
31-40	14
41-50	29
51-60	19
>60	7
Underlying disease	Number (%)
Acute Lymphoblastic Leukemia	24 (27.9%)
Hodgkin’s Disease	6 (7%)
Aplastic Anemia	5 (5.8%)
Acute Myeloid Leukemia	40 (46.5%)
Acute Monocyte Leukemia	6 (7%)
Acute Myelomonocyte Leukemia	5 (5.8%)
Stem cell source	Number (%)
Bone marrow (BM)	0
Cord blood (CB)	0
Peripheral blood stem cell (PBSC)	86 (100%)
Cell dose	No CD34 cell/kg (range)
PBSC	3.73x10^6 (0.6-11.60)
Donor/Recipient (D/R) CMV status	Number (%)
D+/R+	67 (77.9%)
D−/R+	15 (17.4%)
D+/R−	3 (3.5%)
D−/R−	1 (1.2%)

Table 2. Distribution of the analyzed parameters according to the predefined D/R status.

N (%)	D/R status	Median period to first reactivation after the HSCT (days)	Number of reactivations for the observed period (days means)	Duration of DNA-emia/ number of consecutive visits with a positive PCR (days means)	CMV viral load (c/mL mean)
67 (77.9%)	+/+	22.7	2.2	4.7	2 300
15 (17.4%)	−/+	18	2.9	5.2	6 000
3 (3.5%)	+/−	16.5	2.5	4.5	400
1 (1.2%)	−/−	0	0	0	0

Data availability statement

The anonymized data that support the findings of this study are available upon reasonable request from the corresponding author [ZS]. The data are not publicly available due to restrictions, e.g. their containing information that could compromise the privacy of research participants.